Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure

MLA

Stefan Grajek, et al. “Safety, Feasibility and Effectiveness of First in-Human Administration of Muscle-Derived Stem/Progenitor Cells Modified with Connexin-43 Gene for Treatment of Advanced Chronic Heart Failure.” European Journal of Heart Failure, vol. 19, no. 1, Apr. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e71d64ae23817cf96a81521a946aa03&authtype=sso&custid=ns315887.

APA

Stefan Grajek, Bartłomiej Perek, Tomasz Kolanowski, Zofia Oko-Sarnowska, Agnieszka Malcher, Michał Michalak, Maciej Kurpisz, Natalia Rozwadowska, Aleksandra Ciepłucha, Witold Cholewinski, Wojciech Seniuk, Adrian Gwizdała, & Ewa Straburzyńska-Migaj. (2016). Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure. European Journal of Heart Failure, 19(1).

Chicago

Stefan Grajek, Bartłomiej Perek, Tomasz Kolanowski, Zofia Oko-Sarnowska, Agnieszka Malcher, Michał Michalak, Maciej Kurpisz, et al. 2016. “Safety, Feasibility and Effectiveness of First in-Human Administration of Muscle-Derived Stem/Progenitor Cells Modified with Connexin-43 Gene for Treatment of Advanced Chronic Heart Failure.” European Journal of Heart Failure 19 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e71d64ae23817cf96a81521a946aa03&authtype=sso&custid=ns315887.